RQM+โ€™s Post

View organization page for RQM+, graphic

22,964 followers

Absolutely incredible discussion during RQM+ Live! today. ๐Ÿ”ฅ If you missed it, our team was joined by Erik Vollebregt, Heike Moehlig-Zuttermeister, and Donielle Johnson to discuss the latest MDR and IVDR amendments. The short presentation and panel discussion are now available on demand. โ†™๏ธ ๐Ÿ”— https://lnkd.in/eU-Mka5P In the words of attendees... ๐Ÿ’ฌ "๐˜–๐˜ถ๐˜ต๐˜ด๐˜ต๐˜ข๐˜ฏ๐˜ฅ๐˜ช๐˜ฏ๐˜จ ๐˜ข๐˜ด ๐˜ข๐˜ญ๐˜ธ๐˜ข๐˜บ๐˜ด ๐˜ข๐˜ฏ๐˜ฅ ๐˜จ๐˜ณ๐˜ฆ๐˜ข๐˜ต ๐˜ฑ๐˜ณ๐˜ฆ๐˜ด๐˜ฆ๐˜ฏ๐˜ต๐˜ฆ๐˜ณ๐˜ด / ๐˜ฑ๐˜ข๐˜ฏ๐˜ฆ๐˜ญ ๐˜ฅ๐˜ช๐˜ด๐˜ค๐˜ถ๐˜ด๐˜ด๐˜ช๐˜ฐ๐˜ฏ ๐˜ฐ๐˜ฏ ๐˜ข ๐˜ฌ๐˜ฆ๐˜บ ๐˜ณ๐˜ฆ๐˜ญ๐˜ฆ๐˜ท๐˜ข๐˜ฏ๐˜ต ๐˜ต๐˜ฐ๐˜ฑ๐˜ช๐˜ค." ๐Ÿ’ฌ "๐˜›๐˜ฉ๐˜ข๐˜ฏ๐˜ฌ๐˜ด ๐˜ง๐˜ฐ๐˜ณ ๐˜ด๐˜ฉ๐˜ข๐˜ณ๐˜ช๐˜ฏ๐˜จ ๐˜บ๐˜ฐ๐˜ถ๐˜ณ ๐˜ช๐˜ฏ๐˜ด๐˜ช๐˜จ๐˜ฉ๐˜ต๐˜ด, ๐˜ฎ๐˜ข๐˜ฌ๐˜ฆ๐˜ด ๐˜ช๐˜ต ๐˜ฎ๐˜ฐ๐˜ณ๐˜ฆ ๐˜ณ๐˜ฆ๐˜ข๐˜ญ!" ๐Ÿ’ฌ "๐˜๐˜ฐ๐˜ถ๐˜ฏ๐˜ฅ ๐˜ต๐˜ฉ๐˜ฆ ๐˜ธ๐˜ฆ๐˜ฃ๐˜ช๐˜ฏ๐˜ข๐˜ณ ๐˜ณ๐˜ฆ๐˜ข๐˜ญ๐˜ญ๐˜บ ๐˜ถ๐˜ด๐˜ฆ๐˜ง๐˜ถ๐˜ญ ๐˜ข๐˜ด ๐˜ฃ๐˜ข๐˜ด๐˜ฆ๐˜ฅ ๐˜ฐ๐˜ฏ ๐˜ค๐˜ถ๐˜ณ๐˜ณ๐˜ฆ๐˜ฏ๐˜ต ๐˜ฅ๐˜ฆ๐˜ท๐˜ฆ๐˜ญ๐˜ฐ๐˜ฑ๐˜ฎ๐˜ฆ๐˜ฏ๐˜ต๐˜ด ๐˜ณ๐˜ข๐˜ต๐˜ฉ๐˜ฆ๐˜ณ ๐˜ต๐˜ฉ๐˜ข๐˜ฏ ๐˜ข๐˜ฏ ๐˜ช๐˜ฏ๐˜ต๐˜ณ๐˜ฐ ๐˜ต๐˜ฐ ๐˜ฅ๐˜ฆ๐˜ท๐˜ช๐˜ค๐˜ฆ ๐˜ณ๐˜ฆ๐˜ฒ๐˜ถ๐˜ช๐˜ณ๐˜ฆ๐˜ฎ๐˜ฆ๐˜ฏ๐˜ต๐˜ด." ๐Ÿ’ฌ "๐˜“๐˜ฐ๐˜ท๐˜ฆ๐˜ฅ ๐˜ต๐˜ฉ๐˜ฆ ๐˜ฅ๐˜ช๐˜ด๐˜ค๐˜ถ๐˜ด๐˜ด๐˜ช๐˜ฐ๐˜ฏ ๐˜ง๐˜ฐ๐˜ณ๐˜ฎ๐˜ข๐˜ต." Here's an excerpt from Edward B. that articulates the complexities and ambiguities manufacturers face. #MedTech #EUMDR #IVDR #RegulatoryAffairs #SupplyChain

Geethapriya Setty., PMP

Manager, Regulatory Affairs-Edwards Lifesciences

5d

The discussion was highly informative and insightful. A follow-up session could be valuable to address the audience's many unanswered questions. All speakers demonstrated deep expertise, and Erik's funny yet engaging style was the highlight of this discussion.

To view or add a comment, sign in

Explore topics